These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 15585492)

  • 21. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma.
    Iwamoto FM; Schwartz J; Pandit-Taskar N; Peak S; Divgi CR; Zelenetz AD; Humm J; Abrey LE
    Cancer; 2007 Dec; 110(11):2528-34. PubMed ID: 17932895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step.
    Otte A; van de Wiele C; Dierckx RA
    Nucl Med Commun; 2009 Jan; 30(1):5-15. PubMed ID: 19020470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrence of Hodgkin's disease after indium-111 and yttrium-90 labeled antiferritin administration.
    Vriesendorp HM; Quadri SM; Andersson BS; Wyllie CT; Dicke KA
    Cancer; 1997 Dec; 80(12 Suppl):2721-7. PubMed ID: 9406730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is high-dose radioimmunotherapy needed in non-Hodgkin's lymphoma? Against.
    von Schilling C
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1254-6. PubMed ID: 12418478
    [No Abstract]   [Full Text] [Related]  

  • 25. Is high-dose radioimmunotherapy needed in non-Hodgkin's lymphoma? For.
    Behr TM
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1248-54. PubMed ID: 12418465
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).
    DeNardo GL
    Semin Nucl Med; 2005 Jul; 35(3):202-11. PubMed ID: 16098294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mouse models for internal radiation dosimetry.
    Fisher DR; Hui TE
    J Nucl Med; 1999 Nov; 40(11):1969-70. PubMed ID: 10565797
    [No Abstract]   [Full Text] [Related]  

  • 28. Radioimmunotherapy for lymphoma.
    Zelenetz AD
    Curr Opin Oncol; 1999 Sep; 11(5):375-80. PubMed ID: 10505774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensity-modulated radiotherapy for lymphoma involving the mediastinum.
    Goodman KA; Toner S; Hunt M; Wu EJ; Yahalom J
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):198-206. PubMed ID: 15850922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
    Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
    Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa.
    Shome D; Esmaeli B
    Curr Opin Ophthalmol; 2008 Sep; 19(5):414-21. PubMed ID: 18772675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishing a radioimmunotherapy outpatient care clinic for Non-Hodgkin's lymphoma.
    Hendrix C; de Leon C
    Semin Oncol Nurs; 2002 Feb; 18(1 Suppl 1):22-9. PubMed ID: 11878048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Macromolecular approach for targeted radioimmunotherapy in non-Hodgkin's lymphoma.
    Hee C; Ho D; Karton A; Nealon G; Kretzmann JA; Norret M; Iyer KS
    Chem Commun (Camb); 2019 Nov; 55(96):14506-14509. PubMed ID: 31735949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Choosing the right radionuclide and antibody for intraperitoneal radioimmunotherapy.
    Larson SM
    J Natl Cancer Inst; 1991 Nov; 83(22):1602-4. PubMed ID: 1749008
    [No Abstract]   [Full Text] [Related]  

  • 35. Reproducibility of operator processing for radiation dosimetry.
    Shen S; DeNardo GL; DeNardo SJ; Yuan A; DeNardo DA; Lamborn KR
    Nucl Med Biol; 1997 Jan; 24(1):77-83. PubMed ID: 9080478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging radiolabeled therapies hold promise for treatment of cancer.
    Kotz D
    J Nucl Med; 1997 Oct; 38(10):19N, 23N, 39N. PubMed ID: 9379220
    [No Abstract]   [Full Text] [Related]  

  • 37. Reply to letter re: general theory of predictive dosimetry for yttrium-90 radioembolization to sites other than the liver.
    Muylle K; Vanderlinden B
    Cardiovasc Intervent Radiol; 2014 Aug; 37(4):1118-9. PubMed ID: 24218175
    [No Abstract]   [Full Text] [Related]  

  • 38. Radiation nephropathy caused by yttrium 90.
    Cohen EP; Moulder JE; Robbins ME
    Lancet; 2001 Sep; 358(9287):1102-3. PubMed ID: 11594331
    [No Abstract]   [Full Text] [Related]  

  • 39. Erratum for 'Presidential address: systemic radiotherapy--the new frontier' by S. Order.
    Vriesendorp HM
    Int J Radiat Oncol Biol Phys; 1991 Nov; 21(6):1676. PubMed ID: 1938579
    [No Abstract]   [Full Text] [Related]  

  • 40. The effect of local infiltration of a heterologous antiserum of lymphoma cutis in man.
    GRACE JT; GOLLAN F; TAYLOR WL; CARLSON RI
    Surg Forum; 1957; 8():185-7. PubMed ID: 13529581
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.